Cargando…
Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience
For recipients of allogeneic hematopoietic stem cell transplant (HSCT), mycophenolate mofetil (MMF) plus tacrolimus combination is mostly used in reduced-intensity (RIC), and nonmyeloablative conditioning (NMAC) whereas methotrexate and tacrolimus combination is preferred in myeloablative conditioni...
Autores principales: | Hashmi, Hamza, Bhandari, Shruti, Dhanoa, Jugraj, Wu, Xiaoyong, Rai, Shesh, Figg, Lindsay, Baize, Timothy, Krem, Maxwell, Hegazi, Mohamed, Emmons, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058400/ https://www.ncbi.nlm.nih.gov/pubmed/32190456 http://dx.doi.org/10.7759/cureus.6893 |
Ejemplares similares
-
Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023) -
Trigeminal Amyloidoma: Case Report and Review of Literature
por: Hashmi, Hamza, et al.
Publicado: (2018) -
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant
por: Rubinstein, Jeremy D., et al.
Publicado: (2022) -
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis
por: Murthy, Hemant S., et al.
Publicado: (2023) -
Therapeutic drug monitoring of enteric-coated mycophenolate sodium by limited sampling strategies is associated with a high rate of failure
por: Hougardy, Jean-Michel, et al.
Publicado: (2016)